ApertoConsorzio / Partenariato

Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications

Ente erogante: Commissione Europea - Horizon Europe

Scadenza

13 aprile 2027

361 giorni rimanenti

Forma

Non specificata

Budget totale

Non specificato

Contributo max

Non specificato

Descrizione del bando

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:Patients benefit from decreased incidence of Adverse Drug Reactions (ADRs) caused by the administration of multiple medications (three or more medicinal products[1]) and enhanced health outcomes by ensuring safer and more effective use of medication.Healthcare professionals can adopt adverse drug reactions prevention and reduction strategies to integrate genetic and other biomarker information into clinical decision-making to optimise the use of medication, especially in situations of comorbidities.Healthcare systems benefit from cost savings thanks to reduced hospital admissions and other costs associated with ADRs related to the intake of multiple medicines.Clinical and regulatory guidelines and policies for medication management in case of multiple medications can be revised supported by robust evidence.Educational programs for healthcare providers and patients benefit from improved awareness and management of polypharmacy and ADRs. Scope:While medicinal products contribute considerably to the health of EU citizens, they can also have adverse reactions. It is estimated that around 5% of all hospital deaths are due to an adverse drug reaction. On average, 16% of hospitalised older[2] patients experience significant ADRs, varying in severity and mostly preventable, with commonly prescribed drug classes (such as diuretics, anti-bacterials, antithrombotic agents, analgesics, antineoplastics, etc.) accounting for most ADRs[3]. Overall, ADRs increase morbidity, mortality, hospitalisations, and healthcare costs.ADRs from multiple medications contribute significantly to healthcare costs due

Non capisci questo bando?

L'AI di Bandiora te lo spiega in modo semplice: requisiti, importi, scadenze e a chi è rivolto, tutto chiaro.

Registrati e fatti spiegare il bando dall'AI

Area geografica

eu

Tematiche

ricerca e innovazionehealthcarefarmaciadverse drug reactionspolypharmacypersonalised medicinebiomarkersclinical pharmacology

Requisiti dettagliati

Questo bando è rivolto a 3 tipologie di impresa in 3 settori ATECO nell'area eu.

Scopri con l'AI se questo bando è adatto alla tua azienda

Analisi automatica di compatibilità, requisiti e matching in tempo reale

Prova gratis 7 giorni

Questo bando fa per la tua azienda?

L'AI di Bandiora analizza la compatibilità con la tua azienda in tempo reale e ti assiste nella compilazione della candidatura, passo dopo passo.

Altri bandi che potrebbero interessarti

Ultimo aggiornamento: 17 aprile 2026